AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03891602 — intervention group
Intervention type: BEHAVIORAL
Intervention: Primary Care Clinicians' Lung Cancer Screening Survey
Description: Includes items to assess attitudes, barriers, and knowledge of lung cancer screening guidelines.
Study NCT04656249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Drug doses for BTC are identical, being orally administered at 8mg/d to patients weighing \<60 kg and 12mg/d to those ≥60 kg.
Study NCT01659762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous mesenchymal stromal cell
Study NCT05935449 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Formaderm Lidocaine
Description: Dermal filler injection to facial areas
Study NCT05935449 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Formaderm Dermal Filler Injection
Description: Dermal filler injection to facial areas
Study NCT00658203 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New Living CHF
Description: PEA CRT optimization
Study NCT00658203 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: New Living CHF
Description: Standard optimized CRT.
Study NCT02787148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Study NCT03588312 — intervention group
Intervention type: PROCEDURE
Intervention: Aortoplasty using autologous pericardial patch
Description: hypoplastic aortic arch repair using a glutaraldehyde treated, autologous pericardial patch.
Study NCT02158949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mROAD
Study NCT01977131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cells
Study NCT02351050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonolysis
Description: continual transcranial Doppler monitoring of middle cerebral artery
Study NCT02351050 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham procedure
Description: sham transcranial Doppler monitoring of middle cerebral artery
Study NCT00461591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apaziquone
Description: A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
Study NCT00461591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single intravesical dose of placebo instilled into the bladder post-TURBT
Study NCT00461591 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TURBT
Description: TransUrethral Resection of the Bladder Tumor
Study NCT00461591 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TURBT
Description: TransUrethral Resection of the Bladder Tumor
Study NCT03726242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levcromakalim
Description: To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
Study NCT03726242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levcromakalim
Description: To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
Study NCT03726242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
Study NCT03726242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
Study NCT02043626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DISTRICT WELLNESS COMMITTEE
Description: Three Targeted Schools (N+PA) will expand the District's school based wellness initiative, PAW-Physical Activity and Wellness. With District support, PAW schools develop School Wellness Teams (SWTs) to identify school health priorities, implement and sustain health initiatives through school campaigns, promote healthy behavior, and support wellness policies. Results from a 3-year evaluation suggest significant and sustained positive impact on school health culture, student behavior, time-on-task, and increased physical activity among students.
Study NCT02043626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NUTRITIONAL QUALITY OF FOODS AND BEVERAGES ON CAMPUS
Description: Policy changes will focus on 6 target schools. District will expand nutrition education by integrating other opportunities to learn and practice healthy behaviors across disciplines. Farm-to-School programs will include school visits by farmers to teach students about agriculture, healthy foods and nutrition, coinciding with Farmer's Market Menu Days. Schools will receive four 45 minute nutrition workshops per year. Community educators will offer culturally appropriate, interactive nutrition workshops and cooking demonstrations. Cafeterias will receive youth friendly nutritional messaging, regular promotion of new menu foods, and a variety of monthly nutrition-focused activities. The goals are to: increase number of students who try new menu items regularly, increase acceptance of healthy foods, and improve nutrition literacy. Policy states schools will limit celebrations that involve food to no more than 1 per class/month: 6 schools will pilot alternatives to food for celebrations.
Study NCT00711295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted
Description: Intramuscular injection of 3.75 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.
Study NCT01071915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix 240/80 mg
Description: The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenance doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to day 168.
Study NCT03365362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-Term Varenicline
Description: Varenicline tablet x 24 weeks
Study NCT03365362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short-Term Varenicline
Description: varenicline tablet for 12 weeks, followed by placebo tablet manufactured to mimic varenicline 1 mg tablet
Study NCT03365362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Directly Observed Therapy
Description: Varenicline doses are administered by opioid treatment program nurses
Study NCT03365362 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self Administered Therapy
Description: Varenicline doses are self-administered
Study NCT03431714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate amodiaquine
Description: Drugs were administered under observation of the study nurse for three days
Study NCT03845686 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Perfusion functional Magnetic Resonance Imaging (perfusion fMRI)
Description: The goal of this test is to measure brain activity during subacute and chronic post-stroke period using a widely available non-invasive neuroimaging tool - functional Magnetic Resonance Imaging (fMRI). Because fMRI relies in part on cerebral blood flow, which is altered in stroke, measuring longitudinal changes in neural activity with fMRI requires that we control for concomitant changes in blood circulation. To do this, we will employ a novel dual-echo perfusion fMRI sequence, which will allow us to separately estimate neural and vascular contributions to fMRI.
Study NCT01288807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipram
Description: Titration to 200mg PO daily
Study NCT00711243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.
Study NCT02052752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Benzoyl Peroxide
Description: Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
Study NCT02052752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% Benzoyl Peroxide Placebo
Description: The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
Study NCT02052752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neutrogena Rapid Clear®
Description: A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
Study NCT02257229 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical
Description: Surgery only
Study NCT02257229 — intervention group
Intervention type: PROCEDURE
Intervention: Non-Surgical
Description: non-surgical methods such as, casting, bracing, physical therapy, and other.
Study NCT02257229 — intervention group
Intervention type: PROCEDURE
Intervention: Non-surgical + surgical
Description: Combination of non-surgical methods subsequently followed by surgery
Study NCT03558919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 25mg
Study NCT03558919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin Succinate 5 MG
Study NCT04406896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selatogrel
Description: A single subcutaneous injection of 16 mg.
Study NCT04796363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block with Bubivacaine
Description: Erector Spinae Plane Block with Bubivacaine 0.25% or 0.125% before breast cancer surgery
Study NCT04796363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block with Bubivacaine
Description: Erector Spinae Plane Block with Bubivacaine 0.25% or 0.125% before breast cancer surgery
Study NCT04796363 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard General Anaesthesia
Description: Standard General Anaesthesia without ESPB
Study NCT00797849 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Farabloc Limb Cover
Description: Wear prosthetics, sock or glove laminated with Farabloc
Study NCT00797849 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Limb Cover
Description: Wear prosthetics, sock or glove laminated with sham material
Study NCT04526223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comprehensive treatment regimen
Description: 1. Diagnosis MF(includ Post-ET,Post-PV,PMF，MDS/MPN with MF)~2. With at least two month Ruxolitinib treatment prior to transplantation~3. DAC+BF as myeloablative conditioning regimen~4. received Rux at +5d in ASCT and continued to +60d
Study NCT02915042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Analgesic Efficacy
Study NCT02915042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo
Study NCT00997282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-262 2.5 mg
Description: orally administered once daily for 24 weeks
Study NCT00997282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-262 5 mg
Description: orally administered once daily for 24 weeks
Study NCT00997282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally administered once daily for 24 weeks
Study NCT01559272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone IR (Period 1)
Description: Type= exact number, unit= mg, number=1, form= injection, route= intramuscular use. Single injection with 1 mg paliperidone IR in the gluteal or deltoid muscle.
Study NCT00993434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Booklet on nutrition and physical activity.
Description: Parents will be asked to read the booklet and complete a pre- and post-questionnaire.
Study NCT00993434 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Safety Booklet
Description: Parents will be asked to read a safety booklet and complete a pre- and post-questionnaire.
Study NCT02043626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HEALTH PROMOTION AND MARKETING
Description: SWP addresses health promotion and marketing by limiting product marketing in schools, expanding nutrition education and broadening health communication with parents. In 3 targeted schools, we expand to include Staff Wellness Promotion. Adults in schools are trusted and influential role models for students; by increasing their positive health behaviors, students may be influenced to adopt similar behaviors. The District will work with the City's Employee Wellness Program to increase school staff participation.
Study NCT02043626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OPPORTUNITIES FOR PHYSICAL ACTIVITY
Description: District-wide policies include mandates for daily physical activity and PE and development of policies that prohibit withholding PE for punitive reasons. To further increase physical activity, the School Wellness Policy specifies expanding programs/activities that meet need, interest, and abilities of students. Exer-gaming consoles will be provided to 6 schools and will be integrated into 5th-8th grade PE classes and after-school programs. New and innovate gym equipment will be purchased for the 6 target schools for use in gym class and after school programming. Various pedometer and interactive programs encouraging physical activity in and outside of school are planned for the 6th grade.
Study NCT04115800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liposomal Sirolimus
Description: Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease
Study NCT01559272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel A: treatment group 1)
Description: Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique A, in the gluteal muscle.
Study NCT01559272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel A: treatment group 2)
Description: Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique B, in the gluteal muscle.
Study NCT01559272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel B: treatment group 1)
Description: Type= exact number, unit= mg, number= 75, form= injection, route= intramuscular use. Single injection with 75 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
Study NCT03217929 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-taVNS
Description: Regarding sham protocol, the device will be turned off after 60 seconds of stimulation without the knowledge of the patient. After this initial period, the referred paresthesia seems to diminish due to nerve accommodation.
Study NCT02624284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: Active tDCS: A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA to 2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).~Sham tDCS: During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS.
Study NCT02624284 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: Active tDCS: A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA to 2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).~Sham tDCS: During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS.
Study NCT02160366 — intervention group
Intervention type: OTHER
Intervention: Biomarker Research
Description: Research studies on new biomarkers conducted on previously banked blood and/or tumor tissue. Samples collected may include blood, fresh tumor tissue, urine, saliva, bone marrow, pleural fluid, ascites, skin or hair follicle.
Study NCT01782313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tivozanib
Description: Given PO
Study NCT01782313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04061694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate loading, fully guided surgery and 3D printed restoration
Description: Fully guided surgery installation of single dental implants. 3D printed restorations that were immediate loaded.
Study NCT04061694 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Immediate loading
Description: Only subjected to immediate loading. Conventional procedure.
Study NCT01574872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Halotherapy
Description: The treatment consist of 15 session of micronized iodized salt (sodium chloride) skin exposure in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
Study NCT01574872 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment consist of 15 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
Study NCT00647699 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: riboflavin ophthalmic solution
Description: riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
Study NCT00647699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: riboflavin ophthalmic solution
Description: riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
Study NCT01559272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel B: treatment group 2)
Description: Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
Study NCT01559272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel B: treatment group 3)
Description: Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
Study NCT01559272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel B: treatment group 4)
Description: Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
Study NCT01559272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel B: treatment group 5)
Description: Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
Study NCT01559272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F016
Description: Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F016 in the gluteal muscle.
Study NCT01559272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel D: treatment group 1)
Description: Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
Study NCT00647699 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UVA Irradiation
Description: UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
Study NCT01559272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel D: treatment group 2)
Description: Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
Study NCT01559272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate F015 (Panel D: treatment group 3)
Description: Type= exact number, unit= mg, number=350, form= injection, route= intramuscular use. Single injection with 350 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.